Business
MacroGenics Provides Update on Corporate Progress and 2024 Financial Results
Fully enrolled LORIKEET, a randomized 150-patient Phase 2 study of lorigerlimab in combination with docetaxel in patients with mCRPCInitiating new LINNET Phase 2 study of lorigerlimab in ovarian cancerAdvancing multiple novel topoisomerase 1 inhibitor-based ADCs, including MGC026, MGC028 and MGC030Discontinuing further internal clinical development of vobra duo; exploring potential partneringCash, cash equivalents and marketable securities of $201.7 million as of December 31, 2024; cash runway e
About this update from Macrogenics, Inc.
[{"type":"image","alt":"MacroGenics, Inc.","displaySize":"","headline":null,"caption":"MacroGenics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":174,"url":"https://media.zenfs.com/en/globenewswire.com/030baacf51876057e118509310b3ec94"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/C1zbN.lNvnReOeBuDRQ_Bg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTI0NDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/030baacf51876057e118509310b3ec94","width":300,"height":174}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Fully enrolled LORIKEET, a randomized 150-patient Phase 2 study of lorigerlimab in combination with docetaxel in patients with mCRPC","length":132,"tagName":"p"}]},{"val":[{"type":"text","content":"Initiating new LINNET Phase 2 study of lorigerlimab in ovarian cancer","length":69,"tagName":"p"}]},{"val":[{"type":"text","content":"Advancing multiple novel topoisomerase 1 inhibitor-based ADCs, including MGC026, MGC028 and MGC030","length":98,"tagName":"p"}]},{"val":[{"type":"text","content":"Discontinuing further internal clinical development of vobra duo; exploring potential partnering","length":96,"tagName":"p"}]},{"val":[{"type":"text","content":"Cash, cash equivalents and marketable securities of $201.7 million as of December 31, 2024; cash runway extended into the second half of 2026","length":141,"tagName":"p"}]},{"val":[{"type":"text","content":"Conference call scheduled for today at 4:30 p.m. ET ","length":51,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":587,"olType":false},{"type":"text","content":"ROCKVILLE, Md., March 20, 2025 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today provided an update on its recent corporate progress and reported financial results for the year ended December 31, 2024.","length":382,"tagName":"p"},{"type":"text","content":""We concluded 2024 with the achievement of multiple clinical development milestones, including the completion of enrollment in the LORIKEET Phase 2 study evaluating lorigerlimab in combination with docetaxel in patients with mCRPC. We look forward to building upon this momentum in 2025 as we work to advance our novel pipeline of c...